Our ability to perform a detailed assessment of subsequent neoplasms among HCT recipients in the CCSS is limited only to descriptive analysis due to the relatively small number of survivors who received transplantation. Furthermore, we do not have the ability to distinguish between allogeneic vs autologous HCT or to identify survivors with GVHD. Among the 23 603 survivors included in the cohort, 893 had HCT, and of those, only 75 experienced some type of subsequent neoplasm. By decade of diagnosis, for the 1970s, of 44 survivors who received HCT, 14 experienced 71 subsequent neoplasms (9 malignancies, 1 meningioma, and 61 nonmelanoma skin cancers [1 squamous cell carcinoma]); for the 1980s, of 270 survivors who received HCT, 40 experienced 87 subsequent neoplasms (25 malignancies, 1 meningioma, and 61 nonmelanoma skin cancers [0 squamous cell carcinomas]); for the 1990s, of 579 survivors who received HCT, 21 experienced 27 subsequent neoplasms (19 malignancies, 2 meningiomas, and 6 nonmelanoma skin cancers [1 squamous cell carcinoma]). The cumulative incidence of subsequent neoplasms and subsequent malignant neoplasms at 15 years since childhood cancer diagnosis, with 95% confidence intervals, are provided in the Table. However, within the limitations of these small numbers of transplanted patients, we have insufficient power for formal subgroup analysis.The use of HCT, both autologous and allogeneic, increased greatly over the period encompassed by the CCSS cohort ), 1 consistent with the CCSS cohort transplant numbers. Over these decades, a clear trend in the cumulative incidence of subsequent neoplasms or subsequent malignant neoplasms was not observed (Table ). It is important to note, however, that the CCSS cohort was not designed to address HCT-specific late effects. This has become a research priority for the National Institutes of Health. 2 Subsequent neoplasms are a well-known cause of morbidity and mortality following HCT, 3,4 but, to our knowledge, changes in incidence and risk over time have not been examined. As the indications for and survival following HCT continue to increase, the importance of HCT-focused survivorship research also increases and col-laborative studies, similar to what has been done with the CCSS, are required to address the important issue of subsequent neoplasms following HCT.